Back to the main directory
EarningsReview / Equity
- Indutrade (Hold, TP: SEK300.00) - Consistency in action by DnB Markets
- Protector (Buy, TP: NOK370.00) - Profitable growth set to continue by DnB Markets
- Storebrand (Buy, TP: NOK149.00) - Strong start to the year by DnB Markets
- Itaú BBA on Cruzeiro do Sul: Healthy Top-Line Trends; Pressured Margins by Itau
- Food fight - making cuts before the weigh-in by BNP Paribas Exane
- Updating forecasts ahead of FY reporting by BNP Paribas Exane
- Thoughts into Q1 results by BNP Paribas Exane
- European Software / IT Services monthly: March digest by BNP Paribas Exane
- False start by BNP Paribas Exane
- Key take-aways: WSM group investor lunch by BNP Paribas Exane
- A. P. Moller - Maersk - Caught in limbo by Danske Bank Equity Research
- 1Q25 update - better than feared by BNP Paribas Exane
- Gentili Mosconi - Andrà Tutto Bene! by MidCap Partners
- Solutions 30 - Objectif d’EBITDA juste atteint, perspectives favorables by MidCap Partners
- Solutions 30 - EBITDA target just met, favourable outlook by MidCap Partners
- Osmosun - 2024 Revenue by MidCap Partners
- 1Q25 preview: BNPPe 1%/2% above sales / ul. EBITDA by BNP Paribas Exane
- Kantar shows March sales slowdown; 12-week data shows TSCO continuing to make material gains, though discounters accelerating by BNP Paribas Exane
- Sticking our NEC out - a bit more by BNP Paribas Exane
- Feedback post company contact by BNP Paribas Exane
- Q1 pre close feedback: on track for FY guide, growth still to be H2 weighted by BNP Paribas Exane
- Itaú BBA on Orizon: In Line Results, But Solid Upward Trend On Gate Fees by Itau
- US Spirits Data (Nielsen, Mar/Q1’25): Pernod now outperforming Diageo by BNP Paribas Exane
- US Beer Data (Nielsen, Mar/Q1’25): Q1 beer vols. c.-4% by BNP Paribas Exane
- Greenouts are back by BNP Paribas Exane
- Dometic (Buy, TP: SEK60.00) - Another organic growth hit in Q1e by DnB Markets
- YIT (Sell, TP: EUR1.75) - No KPI or EBIT recovery in Q1e by DnB Markets
- Resetting expectations by BNP Paribas Exane
- What’s the buzz? by BNP Paribas Exane
- Digital Industries recovery to continue by BNP Paribas Exane
- Thoughts into Q1 results by BNP Paribas Exane
- Look beyond Germany by BNP Paribas Exane
- Everything is on the Table: 4Q EPS Preview; Cautiously Biased by BNP Paribas Exane
- Earning(s) its due by BNP Paribas Exane
- In the Flow by BNP Paribas Exane
- Tariff Round 2 by BNP Paribas Exane
- Osmosun - CA 2024 by MidCap Partners
- Median Technologies - Résultats finaux de l’étude RELIVE : calendrier confirmé dans la detection et le diagnostic du cancer du poumon by MidCap Partners
- Median Technologies - Final Results of the RELIVE Study: Confirmed Timeline for Lung Cancer Detection and Diagnosis by MidCap Partners
- Gentili Mosconi - Andrà Tutto Bene! by MidCap Partners
- Acquires a minority stake in Aiper by BNP Paribas Exane
- Le Pen verdict; positive for French infra stocks? by BNP Paribas Exane
- FCX, STRATEGY, FQM, AAL, STEEL US by BNP Paribas Exane
- INVEST SECURITIES - DRONE VOLT : En mesure de se concentrer sur l'opérationnel - ACHAT vs NEUTRE, OC 0,85€ vs 0,95€ by Invest Securities
- Solid H1 - onwards to the break-up by BNP Paribas Exane
- Danish Competition probe into P&C insurance by BNP Paribas Exane
- U.S. Nielsen Quick Take - Data Ending 03/22/25 by BNP Paribas Exane
- US Food/HPC Data (Nielsen, Mar'25): Danone & consumer health weaker, beauty somewhat improved by BNP Paribas Exane
- US Total Beverages Alcohol Data (Nielsen, Q1’25): further deterioration by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane